Revenue: As of FY2026 Q1, the actual value is USD 563 K, beating the estimate of USD 463.25 K.EPS: As of FY2026 Q1, the actual value is USD -0.09, missing the estimate of USD -0.08.EBIT: As of FY2026 Q1, the actual value is USD -3.514 M.<h4>Segment Revenue</h4>RenovoRx, Inc. reported revenue of $563,000 for the three months ended March 31, 2026, which is a 136% increase compared to $197,000 for the same period in 2025 . This growth was attributed to the commercialization of RenovoCath and its adoption across U.S. cancer centers .<h4>Operational Metrics</h4>Gross profit for the three months ended March 31, 2026, was $479,000, an increase from $103,000 in the prior year period . The gross profit margin was 85.1% for Q1 2026, compared to 52.3% for Q1 2025 . Research and development expenses decreased to approximately $1.2 million for the first quarter of 2026 from approximately $1.6 million year-over-year, primarily due to higher receipts from the TIGeR-PaC clinical trial . Selling, general and administrative expenses increased to approximately $2.7 million for Q1 2026, compared to approximately $1.6 million for Q1 2025, reflecting the company’s commercial infrastructure strategy . Total operating expenses were $3.948 million for Q1 2026, compared to $3.213 million for Q1 2025 . Loss from operations was - $3.469 million for Q1 2026, compared to - $3.110 million for Q1 2025 . The net loss for the quarter ended March 31, 2026, was approximately - $3.5 million, compared to approximately - $2.4 million for the quarter ended March 31, 2025 .Operational highlights include an increase in active commercial cancer center customers from 5 at the beginning of 2025 to 16 as of May 6, 2026 . RenovoRx, Inc. also has a pipeline of 32 additional centers in various stages of evaluation, approval, and onboarding, and anticipates up to 15 TIGeR-PaC Phase III clinical trial sites transitioning to commercial use post-enrollment . The RenovoCath device has been used in 750 successful procedures since its FDA 510(k) clearance in 2014 . As of May 14, 2026, 106 out of 114 required patients (approximately 93%) had been randomized in the Phase III TIGeR-PaC trial, with full enrollment expected by the end of June 2026 . Final data from the TIGeR-PaC trial is anticipated in mid to late 2027 .<h4>Cash and Cash Equivalents</h4>Cash and cash equivalents were approximately $12.4 million as of March 31, 2026 . During the first quarter, RenovoRx, Inc. completed a private placement that generated approximately $10 million in gross proceeds . The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027 .<h4>Unique Metrics</h4>As of March 31, 2026, common shares outstanding totaled 45.05 million . The initial total addressable market (TAM) for RenovoCath as a stand-alone device is estimated to represent an approximately $400 million peak annual U.S. sales opportunity, with long-term potential of several billion dollars as the platform expands into additional solid tumor indications .<h4>Outlook / Guidance</h4>RenovoRx, Inc. reiterated its full-year 2026 revenue guidance of $3 million to $4 million . The company expects continued revenue growth throughout 2026, supported by ongoing cancer center activations and the transition of TIGeR-PaC trial sites to commercial centers after full enrollment . Full enrollment for the TIGeR-PaC trial is projected to be completed by the end of June 2026 .

RenovoRx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 563 K